Cargando…

Antibodies against High Mobility Group Box protein-1 (HMGB1) versus other anti-nuclear antibody fine-specificities and disease activity in systemic lupus erythematosus

INTRODUCTION: The non-histone nuclear protein high mobility group box protein-1 (HMGB1) is typically associated with nucleosomes, but may shuttle between the nucleus and the cytoplasm, and under some conditions also be released extracellularly and participate in systemic inflammation. Monoclonal HMG...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wirestam, Lina, Schierbeck, Hanna, Skogh, Thomas, Gunnarsson, Iva, Ottosson, Lars, Erlandsson-Harris, Helena, Wetterö, Jonas, Sjöwall, Christopher
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4657231/ https://www.ncbi.nlm.nih.gov/pubmed/26596890 http://dx.doi.org/10.1186/s13075-015-0856-2

Ejemplares similares

Serum levels of autoantibodies against C-reactive protein correlate with renal disease activity and response to therapy in lupus nephritis
por: Sjöwall, Christopher, et al.
Publicado: (2009)

Limited Association between Antibodies to Oxidized Low-Density Lipoprotein and Vascular Affection in Patients with Established Systemic Lupus Erythematosus
por: Wirestam, Lina, et al.
Publicado: (2023)

Osteopontin is associated with disease severity and antiphospholipid syndrome in well characterised Swedish cases of SLE
por: Wirestam, Lina, et al.
Publicado: (2017)

Plasma osteopontin versus intima media thickness of the common carotid arteries in well-characterised patients with systemic lupus erythematosus
por: Wirestam, Lina, et al.
Publicado: (2021)

High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus
por: Abdulahad, Deena A, et al.
Publicado: (2011)

Associations between antinuclear antibody staining patterns and clinical features of systemic lupus erythematosus: analysis of a regional Swedish register
por: Frodlund, Martina, et al.
Publicado: (2013)

HMGB1 in Systemic Lupus Erythematosus
por: Liu, Tianye, et al.
Publicado: (2020)

Application of the 2012 Systemic Lupus International Collaborating Clinics classification criteria to patients in a regional Swedish systemic lupus erythematosus register
por: Ighe, Anna, et al.
Publicado: (2015)

Quality of life and acquired organ damage are intimately related to activity limitations in patients with systemic lupus erythematosus
por: Björk, Mathilda, et al.
Publicado: (2015)

Plasma C-Reactive Protein and Pentraxin-3 Reference Intervals During Normal Pregnancy
por: Wirestam, Lina, et al.
Publicado: (2021)

Serum levels of soluble urokinase plasminogen activator receptor in juvenile idiopathic arthritis: a single-center Swedish case-control study
por: Lewander, Per, et al.
Publicado: (2023)

The Complex Role of C-Reactive Protein in Systemic Lupus Erythematosus
por: Enocsson, Helena, et al.
Publicado: (2021)

Serum levels of autoantibodies against monomeric C-reactive protein are correlated with disease activity in systemic lupus erythematosus
por: Sjöwall, Christopher, et al.
Publicado: (2004)

Associations of C-reactive protein isoforms with systemic lupus erythematosus phenotypes and disease activity
por: Karlsson, Jesper, et al.
Publicado: (2022)

Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus
por: Sohrabian, Azita, et al.
Publicado: (2019)

Antibodies against carbamylated proteins and cyclic citrullinated peptides in systemic lupus erythematosus: results from two well-defined European cohorts
por: Ziegelasch, Michael, et al.
Publicado: (2016)

Therapeutic administration of etoposide coincides with reduced systemic HMGB1 levels in macrophage activation syndrome
por: Palmblad, Karin, et al.
Publicado: (2021)

Cytokine active disulfide-HMGB1 increased during severe macrophage activation syndrome
por: Schierbeck, Hanna, et al.
Publicado: (2014)

Usefulness of Clinical and Laboratory Criteria for Diagnosing Autoimmune Liver Disease among Patients with Systemic Lupus Erythematosus: An Observational Study
por: Heijke, Rebecca, et al.
Publicado: (2021)

The majority of Swedish systemic lupus erythematosus patients are still affected by irreversible organ impairment: factors related to damage accrual in two regional cohorts
por: Frodlund, M, et al.
Publicado: (2019)

Inhibition of HMGB1/RAGE-mediated endocytosis by HMGB1 antagonist box A, anti-HMGB1 antibodies, and cholinergic agonists suppresses inflammation
por: Yang, Huan, et al.
Publicado: (2019)

HMGB1, anti-HMGB1 antibodies, and ratio of HMGB1/anti-HMGB1 antibodies as diagnosis indicator in fever of unknown origin
por: Chen, Mingkun, et al.
Publicado: (2021)

Neutrophils—Important Communicators in Systemic Lupus Erythematosus and Antiphospholipid Syndrome
por: Wirestam, Lina, et al.
Publicado: (2019)

Expression of Concern to: Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1)
por: Yang, Huan, et al.
Publicado: (2020)

Retraction Note to: Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1)
por: Yang, Huan, et al.
Publicado: (2020)

Clinical Experience of Proteasome Inhibitor Bortezomib Regarding Efficacy and Safety in Severe Systemic Lupus Erythematosus: A Nationwide Study
por: Walhelm, Tomas, et al.
Publicado: (2021)

Autoantibodies associated with primary biliary cholangitis are common among patients with systemic lupus erythematosus even in the absence of elevated liver enzymes
por: Ahmad, A., et al.
Publicado: (2020)

High mobility group box protein 1 in complex with lipopolysaccharide or IL-1 promotes an increased inflammatory phenotype in synovial fibroblasts
por: Wähämaa, Heidi, et al.
Publicado: (2011)

Antiphospholipid Antibodies in Lupus Nephritis
por: Parodis, Ioannis, et al.
Publicado: (2016)

Expression of concern to: High systematic levels of the cytokine-inducing HMGB1 isoform secreted in severe macrophage activation syndrome
por: Palmblad, Karin, et al.
Publicado: (2020)

Retraction Note to: High systemic levels of the cytokine-inducing HMGB1 isoform secreted in severe macrophage activation syndrome
por: Palmblad, Karin, et al.
Publicado: (2020)

High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease
por: Pisetsky, David S, et al.
Publicado: (2008)

Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus
por: Parodis, Ioannis, et al.
Publicado: (2020)

First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis
por: Faustini, Francesca, et al.
Publicado: (2021)

HMGB1 Promotes Systemic Lupus Erythematosus by Enhancing Macrophage Inflammatory Response
por: Lu, Mudan, et al.
Publicado: (2015)

SARS-CoV-2 Antibody Isotypes in Systemic Lupus Erythematosus Patients Prior to Vaccination: Associations With Disease Activity, Antinuclear Antibodies, and Immunomodulatory Drugs During the First Year of the Pandemic
por: Sjöwall, Johanna, et al.
Publicado: (2021)

Sex differences in clinical presentation of systemic lupus erythematosus
por: Ramírez Sepúlveda, Jorge I., et al.
Publicado: (2019)

Contributions of de novo variants to systemic lupus erythematosus
por: Almlöf, Jonas Carlsson, et al.
Publicado: (2020)

Comparison of Surrogate Markers of the Type I Interferon Response and Their Ability to Mirror Disease Activity in Systemic Lupus Erythematosus
por: Enocsson, Helena, et al.
Publicado: (2021)

C-Reactive Protein Levels in Systemic Lupus Erythematosus Are Modulated by the Interferon Gene Signature and CRP Gene Polymorphism rs1205
por: Enocsson, Helena, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tma02jr5ud9t8rhqbkfr4t6nn9